Half of that--4.3*$300= $1.3B. Could easily have a market cap of 3B.
Not even counting diagnostic potential for Alzheimer's. At any rate when LS expands useage approval and becomes standard of care CAH will charge more than $300. That may even prompt the buyout.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.